Family · gh
CJC-1295
Modified GRF (1-29); CJC-1295 with DAC (Drug Affinity Complex)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH 1-29), chemically modified for greater stability against enzymatic degradation. In its 'DAC' form, the molecule is engineered to covalently bind circulating albumin after injection, which extends its functional half-life from the minutes typical of native GHRH to several days. It acts on pituitary GHRH receptors to stimulate GH release; human pharmacology studies report that despite the prolonged exposure, physiological pulsatile GH secretion patterns are preserved rather than replaced by continuous secretion.
Human evidence comes mainly from two related pharmacology studies in healthy adult volunteers. Teichman et al. (2006) conducted randomized, placebo-controlled, ascending-dose trials showing single injections of CJC-1295 produced dose-dependent, multi-day increases in GH and IGF-1, with an estimated elimination half-life of about 6–8 days. Ionescu & Frohman (2006) analyzed GH secretion patterns during continuous CJC-1295 exposure and found that pulsatility of GH release persisted rather than becoming continuous. These are short-duration pharmacokinetic/pharmacodynamic and safety studies in small cohorts; there is no published long-term controlled-trial evidence on body composition, athletic performance, or anti-aging outcomes in the general population.
- Human pharmacokinetic/pharmacodynamic research on long-acting GHRH analogs
- Research on regulation and persistence of pulsatile GH secretion
Educational overview only — no dosing instructions in the public hub.
Reported effects in the available short-term human trials include injection-site reactions and GH-axis-related effects such as fluid retention, joint discomfort, and altered insulin sensitivity; theoretical concerns associated with sustained GH/IGF-1 elevation (e.g., effects on glucose metabolism and cell growth signaling) have not been assessed in long-term controlled trials. The DAC (albumin-binding) formulation raises additional theoretical questions about immunogenicity and prolonged systemic exposure that are not fully characterized in the public literature. Unregulated research-chemical products carry added risks from unverified purity, sterility, and labeling.
Purity and identity should be verified by an independent third-party laboratory using a method that includes identity confirmation, purity/quantification (e.g., HPLC), and mass spectrometry (MS) — not solely a manufacturer's internal certificate.
Not approved by the FDA, EMA, or MHRA as a drug for human use. It is commonly sold and referenced as a research chemical/RUO (research use only) product rather than a medicine, and is not subject to pharmaceutical manufacturing or pharmacovigilance oversight. Regulatory status varies by jurisdiction and can change.
Frequently asked questions
- What is CJC-1295 used for?
- Human pharmacokinetic/pharmacodynamic research on long-acting GHRH analogs. Research on regulation and persistence of pulsatile GH secretion. Human evidence comes mainly from two related pharmacology studies in healthy adult volunteers. Teichman et al. (2006) conducted randomized, placebo-controlled, ascending-dose trials showing single injections of CJC-1295 produced dose-dependent, multi-day increases in GH and IGF-1, with an estimated elimination half-life of about 6–8 days. Ionescu & Frohman (2006) analyzed GH secretion patterns during continuous CJC-1295 exposure and found that pulsatility of GH release persisted rather than becoming continuous. These are short-duration pharmacokinetic/pharmacodynamic and safety studies in small cohorts; there is no published long-term controlled-trial evidence on body composition, athletic performance, or anti-aging outcomes in the general population.
- Is CJC-1295 legal in Europe?
- Not approved by the FDA, EMA, or MHRA as a drug for human use. It is commonly sold and referenced as a research chemical/RUO (research use only) product rather than a medicine, and is not subject to pharmaceutical manufacturing or pharmacovigilance oversight. Regulatory status varies by jurisdiction and can change.
- What are the risks and side effects of CJC-1295?
- Reported effects in the available short-term human trials include injection-site reactions and GH-axis-related effects such as fluid retention, joint discomfort, and altered insulin sensitivity; theoretical concerns associated with sustained GH/IGF-1 elevation (e.g., effects on glucose metabolism and cell growth signaling) have not been assessed in long-term controlled trials. The DAC (albumin-binding) formulation raises additional theoretical questions about immunogenicity and prolonged systemic exposure that are not fully characterized in the public literature. Unregulated research-chemical products carry added risks from unverified purity, sterility, and labeling.
- How is the quality of CJC-1295 assessed?
- Purity and identity should be verified by an independent third-party laboratory using a method that includes identity confirmation, purity/quantification (e.g., HPLC), and mass spectrometry (MS) — not solely a manufacturer's internal certificate.